AHA 2020 Trial Takeaways: Should Rivaroxaban Be Used in Patients with Bioprosthetic Valves? Can Vitamin D, Omega-3 Supplementation and Early Ablation Decrease the Incidence of Afib and Other CV Events?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

AHA 2020 Trial Takeaways: Should Rivaroxaban Be Used in Patients with Bioprosthetic Valves? Can Vitamin D, Omega-3 Supplementation and Early Ablation Decrease the Incidence of Afib and Other CV Events?

By The North American Thrombosis Forum (NATF) FEATURING Christian Ruff

0 views

December 17, 2020

Comments 1

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

Challenges and Opportunities with Contemporary GDMT in NYHA Class II…

Feat. W. Abraham

11:37

ACC 2022 Conference Coverage

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

Feat. P. Heidenreich

11:25

ACC 2023 Conference Coverage

ACC 2023: SGLT2i Use - Dos and Don'ts

Feat. A. Armbruster

61:49

Obafemi Awolowo University

Management of Heart Failure

Feat. O. A. Akinyele

27:14

MUSC Cardiology

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

Feat. R. Mentz

14:39

Lankenau

Management of AF patients with ACS

Feat. P. Kowey, D. Ice

16:01

Boston Scientific

POLARx™ FIT Cryoballoon: Why Size Matters

Feat. W. Su

09:52

AHA 2022 Conference Coverage

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

Feat. R. Mentz

13:07

Michelle Kittleson

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

18:36

The Texas Heart Institute

Rhythm vs Rate: Has the Tide Changed Since the AFFIRM Trial?

Feat. M. Razavi

35:16

Scripps Health

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Feat. M. Kittleson

57:30

McMaster University Department of Medicine

Five Things Every Internist Should Know About Anticoagulants

Feat. S. Mithoowani

12:30

Houston Methodist Hospital

Amyloidosis Types and Pathophysiology

Feat. B. Trachtenberg

36:11

ARCH Advanced Revascularization Symposium

The UPSTREAM Management of Aortic Stenosis in the Future

Feat. M. Leon

48:35

Houston Methodist DeBakey Heart and Vascular Center

"Pill in Pocket" Anticoagulation for Atrial Fibrillation: …

Feat. R. Passman

15:47

Scripps Health

HFpEF in Women

Feat. B. Borlaug

19:30

ACC 2022 Conference Coverage

Hot Topics in Heart Failure ACC.22

Feat. N. Ibrahim

17:08

CVRx | Barostim

Integrating Barostim into a Comprehensive Heart Failure Program ISHL…

Feat. D. Yaranov, P. Patel, R. Gupta, J. Schmitto, E. Chung

17:29

UCLA Health

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

Feat. D. Vucicevic

12:30

Taya Glotzer

Login

Login

Join VuMedi

AHA 2020 Trial Takeaways: Should Rivaroxaban Be Used in Patients with Bioprosthetic Valves? Can Vitamin D, Omega-3 Supplementation and Early Ablation Decrease the Incidence of Afib and Other CV Events?

Recommended